AbbVie Oxford
Biotech

AbbVie invests £120M in UK, including new R&D headquarters

AbbVie is investing 120 million pounds ($160 million) to expand its U.K. R&D presence, in a show of faith in the country’s life sciences sector.
James Waldron Nov 4, 2026 2:31am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
Money present

Rhythm drums up LG obesity license to as much as $855M

Nov 3, 2026 9:32am
AbbVie booth at AACR 2026

AbbVie drops ph. 2 solid tumor drug over ‘limited benefit’

Nov 3, 2026 8:38am
Pfizer

Pfizer trims obesity pipeline, axes phase 2 lung disease asset

Nov 3, 2026 8:02am
Close-up of shredded document

Novartis scraps $800M BioArctic brain collab after barely a year

Nov 3, 2026 4:53am
More News

FDA grants uniQure priority review of its Huntington’s drug

Nov 2, 2026 4:12pm
Fierce Pharma

Karyopharm files Chapter 11 ahead of Ayrmid merger

Nov 2, 2026 10:46am

Teva ends trial of one of original line-up of innovative meds

Nov 2, 2026 9:22am

Bright Minds seizure study on partial hold over toxicity in mice

Nov 2, 2026 8:43am